Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
about
Pharmacotherapy of systemic sclerosisRaynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and managementSystemic sclerosis: current concepts in pathogenesis and therapeutic aspects of dermatological manifestations.Advances in the treatment of Raynaud's phenomenon.Raynaud's phenomenon (secondary).Novel therapy in the treatment of scleroderma.Development of agents for the treatment of systemic sclerosis.[Oral N-acetylcysteine in the treatment of Raynaud's phenomenon secondary to systemic sclerosis: a randomized, double-blind, placebo-controlled clinical trial].Vascular involvement in systemic sclerosis (scleroderma).Evaluation of test characteristics for outcome measures used in Raynaud's phenomenon clinical trials.Therapeutic options for digital ulcers in patients with systemic sclerosis.Development of a provisional core set of response measures for clinical trials of systemic sclerosis.The challenge of scleroderma ulcers.The pathogenesis, diagnosis and treatment of Raynaud phenomenon.Scleroderma therapy: clinical overview of current trends and future perspective.Systemic sclerosis--challenges for clinical practice.Efficacy of Raynaud's phenomenon and digital ulcer pharmacological treatment in systemic sclerosis patients: a systematic literature review.Optimal management of digital ulcers in systemic sclerosisTherapeutic implications from the pathogenesis of Raynaud's phenomenon.Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon.Digital ischemia in scleroderma spectrum of diseases.Bosentan therapy for patients with severe Raynaud's phenomenon in systemic sclerosis.Efficacy and Safety of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis: A Randomized, Placebo-Controlled, Phase II Study.Points to consider-Raynaud's phenomenon in systemic sclerosis.The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies.Editorial: Clinical Trials in Raynaud's Phenomenon: A Spoonful of Sugar (Pill) Makes the Medicine Go Down (in Flames).A multi-national qualitative research study exploring the patient experience of Raynaud's phenomenon in systemic sclerosis.Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts.
P2860
Q24629481-382BF58E-F806-4B00-BB08-71032A918292Q28392431-89A07480-EC5C-4AE0-AF17-DE8C926E6ABEQ31125829-5115D806-B273-442A-9EAC-C8DCD66788A2Q33813778-2BB16C0B-C3E9-4A0D-9EBA-F5D2E587C004Q34011187-F73EF077-26BA-46B8-9E9A-3A7D30B5A997Q34104580-49949CEC-A805-4C2E-B785-E685425F846EQ34481552-2BBB21EB-405F-4B0C-814C-17420CB1C2F8Q35472514-086B6AEE-18C8-43D1-B9D8-78CC5F7C8838Q35557424-FC559484-008B-4737-8321-FA5861711D27Q36488075-B23AE026-6DCC-4AC9-9D19-233A46F41157Q36835012-422A4B6E-066C-4B36-9623-4568EC88BA04Q37460792-F9268D4C-65ED-4B19-B08D-F00087C17229Q37500626-FD95DF9C-7AA6-45D9-B2A3-8743D5C68465Q38025285-5D4337EE-EB44-42DB-9169-14690FB1530EQ38046467-4B6CBDB8-3B92-409B-97D4-5902BCEC05E0Q38059459-FB2AFC17-1405-4E54-A599-C60D9996A62BQ38396543-6D0C73E8-B336-4EAA-8D72-4B42C57D9577Q38537531-21E427B5-F652-4912-B0F9-2E9D2A2762C3Q39090456-59FE2AB8-9BE5-4E43-969E-F2125F06F3F9Q39632069-068C3BB2-8BCC-48ED-9D23-D4FF590E471BQ39951981-FA38DB44-3A26-42AE-B230-82F79BE91D97Q42339963-D25E05C2-0802-4FEF-8B1A-607D90638238Q47591657-DCC4D444-9420-4352-AB21-454A57C5C8C4Q48531268-9C50B8D7-F8CC-4AE8-93E0-48F7BF54CE5EQ48566617-7AE24455-0B88-4A97-9954-3F3E6BA668A3Q50243982-E9E9F335-AEBF-4ED4-A5D0-7C30D837072AQ52374296-34CF0B98-FB7A-4423-86F3-3DBCE0914CABQ52714555-BBBADD6C-E70D-4E07-9A60-54A68B7D7937
P2860
Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
Oral iloprost treatment in pat ...... ontrolled, double-blind study.
@en
Oral iloprost treatment in pat ...... ontrolled, double-blind study.
@nl
type
label
Oral iloprost treatment in pat ...... ontrolled, double-blind study.
@en
Oral iloprost treatment in pat ...... ontrolled, double-blind study.
@nl
prefLabel
Oral iloprost treatment in pat ...... ontrolled, double-blind study.
@en
Oral iloprost treatment in pat ...... ontrolled, double-blind study.
@nl
P2093
P1476
Oral iloprost treatment in pat ...... ontrolled, double-blind study.
@en
P2093
Collier DH
Jimenez SA
P2860
P304
P356
10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I
P577
1998-04-01T00:00:00Z